二甲双胍对糖尿病合并肺癌患者生存期的影响

The Effects of Metformin on Survival of Diabetic Patients Complicated with Lung Cancer

目的研究二甲双胍对糖尿病合并肺癌患者生存期的影响。方法选取2014年至2016年在我院诊断的糖尿病合并肺癌的患者并服用二甲双胍降糖治疗的患者44例为观察组,同期诊断的糖尿病合并肺癌的患者胰岛素治疗的患者44例为对照组,随访88例患者的生存期。查阅患者的一般资料,如年龄、性别、肺癌的分期、病理分型、远处转移、吸烟、治疗情况、血糖及控制血糖的方法等,随访患者的生存情况。结果两组患者客观疗效比较差异无统计学意义(P>0.05)。将相关因素进行Cox多因素回归分析,患者的生存时间与多发转移、二甲双胍、肿瘤分期、病理分型有关,差异具有统计学意义(P<0.05),而与年龄、性别、吸烟无相关,差异无统计学差异(P>0.05),二甲双胍可以肺癌患者的生存期,差异具有统计学意义(χ~2=16.023,P<0.001)。结论二甲双胍不能改善肺癌患者客观疗效,具有延长肺癌患者长期生存期的作用。

Objective To study the effects of metformin on the survival of patients with diabetes mellitus and lung cancer.Methods We selected 44 patients from 2010 to 2016 with diabetes mellitus complicated with lung cancer treated with metformin as the observation group,also 44 patients with diabetes mellitus complicated with lung cancer treated with insulin as the control group. These patients were followed up for the survival time. We also collected general information of these patients, such as age, sex, staging of lung cancer,pathological classification, distant metastasis, smoking, treatment, blood glucose and blood glucose control methods and followed up the survival of these patients.Results There was no difference in the objective treatment response between the two groups(P>0.05). Cox multivariate regression analysis showed that the survival time of patients was related with multiple metastasis, metformin, tumor stage, and pathological classification(P<0.05),but not related to age, sex, and smoking(P>0.05). Metformin could improve the long-term survival of lung cancer patients with a significant effect(χ~2=16.023,P<0.001).Conclusion Metformin can not improve the short-term efficacy of lung cancer patients, but can improve the long-term survival of lung cancer patients.